Abstract: Antimicrobial activity exhibited against a wide variety of plant pathogens. A functional peptide consisting of the amino acid sequence: YYGFPAFSERTRKFWRIWKGKTS (SEQ ID NO: 1) or an amino acid sequence having an identity of 85% or more with respect to the amino acid sequence, or consisting of a partial peptide thereof.

Abstract: A thermoplastic resin composition, may include a thermoplastic resin (A) and, per 100 parts by mass of the thermoplastic resin (A), from 0 to 0.2 parts by mass of a metal salt-containing flame retardant (B), and not less than 0.05 parts by mass and less than 3 parts by mass of an organopolysiloxane (C), wherein the organopolysiloxane (C) has a molecular weight distribution (Mw/Mn) in a range of from 1.01 to 1.4.

Abstract: A method for detecting a mutation in an amino acid at position 93 of a hepatitis C virus NS5A protein, the method including: synthesizing cDNA using, as a template, hepatitis C virus RNA in a sample; and performing a real-time PCR with a cycling probe method using, as a template, the cDNA; wherein a primer set used in the real-time PCR is a certain primer set; and wherein probes used in the real-time PCR include certain probes.

Abstract: The present invention provides a method for producing an oxymethylene copolymer which involves polymerizing trioxane and a comonomer cationically at a polymerization temperature of 135° C. to 300° C. in the presence of a protic acid salt having the molecular weight of 1000 or less, and at least one polymerization initiator selected from the group consisting of protic acids, protic acid anhydrides, and protic acid ester compounds having the molecular weight of 1000 or less.

Abstract: The invention provides a method for producing an oxymethylene copolymer including a polymerization step for cationically polymerizing trioxane and a comonomer at a polymerization temperature of from 135 to 300° C. in the presence of at least one salt of a protonic acid having a molecular weight of 1,000 or less, and at least one polymerization initiator selected from the group consisting of protonic acids having a molecular weight of 1,000 or less, protonic acid anhydrides having a molecular weight of 1,000 or less, and protonic acid ester compounds having a molecular weight of 1,000 or less; wherein the total concentration of metal components contained in the trioxane and comonomer used in the polymerization step is 300 ppb by mass or less.

Abstract: The invention provides a method for producing an oxymethylene copolymer including a polymerization step for cationically polymerizing trioxane and a comonomer at a polymerization temperature of from 135 to 300° C. in the presence of at least one salt of a protonic acid having a molecular weight of 1,000 or less, and at least one polymerization initiator selected from the group consisting of protonic acids having a molecular weight of 1,000 or less, protonic acid anhydrides having a molecular weight of 1,000 or less, and protonic acid ester compounds having a molecular weight of 1,000 or less; wherein the total concentration of metal components contained in the trioxane and comonomer used in the polymerization step is 300 ppb by mass or less.

Abstract: A method for detecting a mutation in an amino acid at position 93 of a hepatitis C virus NS5A protein, the method including: synthesizing cDNA using, as a template, hepatitis C virus RNA in a sample; and performing a real-time PCR with a cycling probe method using, as a template, the cDNA; wherein a primer set used in the real-time PCR is a certain primer set; and wherein probes used in the real-time PCR include certain probes.

Abstract: The present invention is directed to a method for producing an oxymethylene copolymer by subjecting trioxane and 1,3-dioxolane to copolymerization using boron trifluoride or a coordination compound thereof as a catalyst, wherein the copolymerization is conducted in the presence of a steric-hindrance phenol in an amount of 0.006 to 2.0% by weight, based on the weight of the trioxane, using 0.01 to 0.07 mmol of boron trifluoride or a coordination compound thereof as a catalyst, relative to 1 mol of the trioxane, and wherein, at a point in time when the polymerization yield becomes 92% or more, the formed oxymethylene copolymer and a polymerization terminator are contacted to terminate the polymerization.

Abstract: The present invention provides a method for producing an oxymethylene copolymer which involves polymerizing trioxane and a comonomer cationically at a polymerization temperature of 135° C. to 300° C. in the presence of a protic acid salt having the molecular weight of 1000 or less, and at least one polymerization initiator selected from the group consisting of protic acids, protic acid anhydrides, and protic acid ester compounds having the molecular weight of 1000 or less.

Abstract: The present invention is directed to a method for producing an oxymethylene copolymer by subjecting trioxane and 1,3-dioxolane to copolymerization using boron trifluoride or a coordination compound thereof as a catalyst, wherein the copolymerization is conducted in the presence of a steric-hindrance phenol in an amount of 0.006 to 2.0% by weight, based on the weight of the trioxane, using 0.01 to 0.07 mmol of boron trifluoride or a coordination compound thereof as a catalyst, relative to 1 mol of the trioxane, and wherein, at a point in time when the polymerization yield becomes 92% or more, the formed oxymethylene copolymer and a polymerization terminator are contacted to terminate the polymerization.

Abstract: Disclosed is a method for treating liver injury caused by microorganism or toxic substance, which comprises administering to a patient suffering from liver injury a composition comprising a thrombomodulin, which has the ability to bind to thrombin and promote the activation of protein C by thrombin, as an active ingredient and at least one pharmaceutically acceptable carrier. The method of the present invention is very effective for ameliorating liver injury, such as fulminant hepatitis and hepatic veno-occlusive disease (VOD) which is likely to frequently occur after bone marrow transplantation.